

Supplementary Table S1. Multivariate analysis for PFS taking into consideration baseline prognostic clinicopathological parameters.

| Variable | HR (95% CI) | P |
|-------------------------------------|--------------------|----------|
| Age | | <0.001 |
| <65 | 1 | |
| ≥65 | 1.54 (1.29-1.83) | |
| Stage | | <0.001 |
| I/II | 1 | |
| III/IV | 3.37 (2.34-4.85) | |
| ECOG-PS | | 0.051 |
| 0-1 | 1 | |
| 2-4 | 1.30 (0.99-1.71) | |
| Quality of Debulking surgery | | 0.052 |
| Optimal | 1 | |
| Suboptimal | 1.19 (0.99-1.42) | |
| BMI | | 0.038 |
| <25 | 1 | |
| ≥25 | 0.83 (0.70-0.99) | |
| Histology | | 0.266 |
| Serous | 1 | |
| Mucinous | 1.75 (1.04-2.94) | |
| Endometrioid | 0.95 (0.67-1.34) | |
| Clear Cell | 0.94 (0.67-1.33) | |
| Adenocarcinoma | 1.21 (0.89-1.64) | |

| | | |
|----------------|------------------|--|
| Non-epithelial | 1.09 (0.59-2.02) | |
|----------------|------------------|--|

ECOG-PS: Eastern Cooperative Oncology Group Performance Status, BMI: Body Mass Index

Supplementary Table S2. Clinicopathological characteristics of the subpopulation of patients according to BMI groups.

| Characteristic | BMI 15-24.99 kg/m ² | BMI 25-29.99 kg/m ² | BMI 30-34.99 kg/m ² | BMI>35 kg/m ² | P |
|----------------------------|---------------------------------|---------------------------------|---------------------------------|---------------------------------|-------|
| | Median (25th - 75th percentile) | |
| Age | 58.5 (49.3-67.8) | 61.2 (52.3-70.0) | 64.3 (56.9-71.4) | 59.6 (51.8 – 67.4) | |
| BMI | 22.4 (18.6-23.1) | 26.9 (25.2-28.6) | 31.6 (30.3-32.9) | 37.8 (35.7-41.4) | |
| BSA | 1.56 (1.49-1.63) | 1.69 (1.61-1.77) | 1.77 (1.69-1.85) | 1.93 (1.86-2.07) | |
| | N(%) | N(%) | N(%) | N(%) | |
| ECOG-PS | | | | | 0.470 |
| 0-1 | 415 (87.4%) | 300 (87.2%) | 118 (84.3%) | 64 (83.1%) | |
| ≥2 | 60 (12.6%) | 44 (12.8%) | 22 (15.7%) | 13 (16.9%) | |
| Stage | | | | | 0.195 |
| I/II | 89 (17.8%) | 84 (23.1%) | 36 (23.5%) | 19 (23.7%) | |
| III/IV | 410 (82.2%) | 280 (76.9%) | 117 (76.5%) | 61 (76.3%) | |
| Grade | | | | | 0.517 |
| 1 | 42 (8.9%) | 24 (6.9%) | 15 (10.8%) | 3 (4.1%) | |
| 2 | 121 (25.7%) | 103 (29.9%) | 37 (26.6%) | 22 (29.7%) | |
| 3 | 305 (65.4%) | 218 (63.2%) | 87 (62.6%) | 49 (66.2%) | |
| Histology | | | | | 0.850 |
| Serous | 315 (63.4%) | 239 (65.6%) | 94 (60.3%) | 48 (55.3%) | |
| Mucinous | 30 (6.0%) | 21 (5.8%) | 10 (6.4%) | 1 (1.1%) | |
| Endometrioid | 56 (11.3%) | 44 (12.1%) | 22 (14.1%) | 15 (17.2%) | |
| Clear Cell | 41 (8.2%) | 24 (6.6%) | 12 (7.7%) | 7 (8.0%) | |
| Adenocarcinoma NOS | 41 (8.2%) | 31 (8.5%) | 14 (8.9%) | 7 (8.0%) | |
| Non-epithelial histologies | 14 (2.8%) | 5 (1.4%) | 4 (2.6%) | 3 (3.4%) | |
| Surgery | | | | | 0.326 |
| PDS | 450 (90.2%) | 314 (87.9%) | 131 (86.2%) | 81 (95.3%) | |
| IDS | 29 (5.8%) | 28 (7.8%) | 12 (7.6%) | 3 (3.5%) | |
| No surgery | 20 (4.0%) | 15 (4.2%) | 9 (5.7%) | 1 (1.2%) | |
| Surgical outcome | | | | | 0.517 |
| Complete/Optimal | 230 (48.5%) | 185 (53.2%) | 67 (48.6%) | 35 (45.5%) | |
| Suboptimal | 244 (51.5%) | 163 (46.8%) | 71 (51.4%) | 42 (54.5%) | |

BMI: Body Mass Index, BSA: Body Surface Area, ECOG-PS: Eastern Cooperative Oncology Group Performance Status, PDS: Primary Debulking Surgery, IDS: Interval Debulking Surgery

